HeartFlow Appoints John Farquhar as Chief Operating Officer

HeartFlow Inc. has appointed John Farquhar as chief operating officer to support the execution of the company’s strategic vision.
 
“We are thrilled to add an executive of John’s caliber and accomplishments to the HeartFlow leadership team,” said John H. Stevens, M.D., president, CEO and co-founder of HeartFlow. “In his new role, he will lead and provide strategic oversight of our key operational areas to ensure excellence and disciplined growth as HeartFlow continues to transform the diagnosis and management of coronary artery disease.”
 
Farquhar brings more than 20 years of experience providing strategic oversight to deliver operational excellence and outstanding performance. Most recently, he served as vice president and general manager of Medtronic plc’s Aortic business, delivering strong growth through new product launches. He also served in key leadership roles for Medtronic’s Cardiovascular and Diabetes Groups, including vice president of the Americas region for the Insulin Pump and Continuous Glucose Monitoring business unit and vice president for Asia Pacific.
 
“I am excited to join a company with a compelling vision to change the paradigm for managing and treating heart disease,” said Farquhar. “I look forward to working with the leadership team at HeartFlow to democratize access to this incredible technology.”
 
A native of California, Farquhar earned a bachelor of arts degree from Duke University and his MBA from Northwestern’s Kellogg School of Management.
 
Starting with a standard coronary computed tomography angiogram (CTA), the HeartFlow Analysis leverages deep learning and highly trained analysts to create a digital, personalized 3D model of the heart. The HeartFlow Analysis then uses computer algorithms to solve millions of complex equations to simulate blood flow and provides FFRct values along the coronary arteries. This information helps physicians evaluate the impact a blockage may be having on blood flow and determine the optimal course of treatment for each patient. A positive FFRct value (≤0.80) indicates that a coronary blockage is impeding blood flow to the heart muscle to a degree which may warrant invasive management.
 
Data demonstrating the safety, efficacy and cost-effectiveness of the HeartFlow Analysis have been published in more than 425 peer-reviewed publications, including long-term data out to five years. The HeartFlow Analysis offers the highest diagnostic performance available from a non-invasive test.¹ To date, clinicians around the world have used the HeartFlow Analysis for more than 100,000 patients to aid in the diagnosis of heart disease.
 
HeartFlow is the leader in revolutionizing precision heart care, uniquely combining human ingenuity with advanced technology. HeartFlow’s non-invasive HeartFlow FFRct Analysis leverages artificial intelligence to create a personalized three-dimensional model of the heart. By using this model, clinicians can better evaluate the impact a blockage has on blood flow and determine the best treatment for patients. HeartFlow’s technology is reflective of our Silicon Valley roots and incorporates over two decades of scientific evidence with the latest advances in artificial intelligence. The HeartFlow FFRct Analysis is commercially available in the United States, U.K., Canada, Europe, and Japan. 

Reference 
¹ Driessen, R., et al. J Am Coll Cardiol. 2019;73(2),161-73.